The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Rethinking ovarian cancer: recommendations for improving outcomes
Open accessAbstract
There have been major advances in our understanding of the cellular and molecular biology of the human malignancies that are collectively referred to as ovarian cancer. At a recent Helene Harris Memorial Trust meeting, an international group of researchers considered actions that should be taken to improve the outcome for women with ovarian cancer. Nine major recommendations are outlined in this Opinion article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Self-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“The increased infiltration of lymphocytes in tumour islets predicts significantly longer survival in ovarian cance”
Self-citationDistant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman, R. J., & Shih, I.-M. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf3d79 · Cited by 1,846
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Self-citationHallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Domchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
Cited by
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569
Self-citationEvaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,418
Self-citationRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Self-citationStaging classification for cancer of the ovary, fallopian tube, and peritoneum
Prat, J. (2014) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2013.10.001 · Cited by 1,364
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Self-citationHe, C., Lu, K., Liu, D., & Lin, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4098862 · Cited by 885
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
Kopper, O., de Witte, C. J., Lõhmussaar, K., Valle-Inclan, J. E., Hami, N., Kester, L., Balgobind, A. V., Korving, J., Proost, N., Begthel, H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0422-6 · Cited by 834
Endometriosis: Epidemiology, Diagnosis and Clinical Management
Parasar, P., Ozcan, P., & Terry, K. L. (2017) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-017-0187-1 · Cited by 753
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Lisio, M.-A., Fu, L., Goyeneche, A., Gao, Z.-H., & Telleria, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040952 · Cited by 680
GRP78: A cell's response to stress
Ibrahim, I. M., Abdelmalek, D. H., & Elfiky, A. A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.022 · Cited by 647
Perets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., Chen, J. Y. H., Ohman, A. W., Stepule, C. D., Kwak, S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.013 · Cited by 596
Latest research and treatment of advanced-stage epithelial ovarian cancer
Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489
Self-citationThe Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids
Kessler, M., Hoffmann, K., Brinkmann, V., Thieck, O., Jackisch, S., Toelle, B., Berger, H., Mollenkopf, H.-J., Mangler, M., Sehouli, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9989 · Cited by 459
Copy number signatures and mutational processes in ovarian carcinoma
Macintyre, G., Goranova, T. E., De Silva, D., Ennis, D., Piskorz, A. M., Eldridge, M., Sie, D., Lewsley, L.-A., Hanif, A., Wilson, C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0179-8 · Cited by 449
Self-citationSieh, W., Köbel, M., Longacre, T. A., Bowtell, D. D., deFazio, A., Goodman, M. T., Høgdall, E., Deen, S., Wentzensen, N., Moysich, K. B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70253-5 · Cited by 433
Self-citationThe PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
Mabuchi, S., Kuroda, H., Takahashi, R., & Sasano, T. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.02.003 · Cited by 413
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103988 · Cited by 403
“The remaining histiotypes are mucinous, endometrioid and clear cell [3].”
BackgroundHong, T., Lei, G., Chen, X., Li, H., Zhang, X., Wu, N., Zhao, Y., Zhang, Y., & Wang, J. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101928 · Cited by 373
Vaidyanathan, A., Sawers, L., Gannon, A.-L., Chakravarty, P., Scott, A. L., Bray, S. E., Ferguson, M. J., & Smith, G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.203 · Cited by 364
Sala, E., Rockall, A. G., Freeman, S. J., Mitchell, D. G., & Reinhold, C. (2013) · Radiology · doi:10.1148/radiol.12120315 · Cited by 347
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341
“Despite surgical debulking and administration of platinum-based chemotherapy, almost all patients suffer from recurrent and disseminated disease and the majority dies in less than 5 years (Vaughan et al., 2011).”
BackgroundYokoi, A., Yoshioka, Y., Yamamoto, Y., Ishikawa, M., Ikeda, S.-I., Kato, T., Kiyono, T., Takeshita, F., Kajiyama, H., Kikkawa, F., et al. (2017) · Nature Communications · doi:10.1038/ncomms14470 · Cited by 334
Wnt/β-catenin-driven EMT regulation in human cancers
Xue, W., Yang, L., Chen, C., Ashrafizadeh, M., Tian, Y., & Sun, R. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05099-7 · Cited by 321
Integrated extracellular microRNA profiling for ovarian cancer screening
Yokoi, A., Matsuzaki, J., Yamamoto, Y., Yoneoka, Y., Takahashi, K., Shimizu, H., Uehara, T., Ishikawa, M., Ikeda, S.-I., Sonoda, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06434-4 · Cited by 315
Endometriosis and cancer: a systematic review and meta-analysis
Kvaskoff, M., Mahamat-Saleh, Y., Farland, L. V., Shigesi, N., Terry, K. L., Harris, H. R., Roman, H., Becker, C. M., As-Sanie, S., Zondervan, K. T., et al. (2021) · Human Reproduction Update · doi:10.1093/humupd/dmaa045 · Cited by 303
Böhm, S., Faruqi, A., Said, I., Lockley, M., Brockbank, E., Jeyarajah, A., Fitzpatrick, A., Ennis, D., Dowe, T., Santos, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.5212 · Cited by 303
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
Wilson, M. K., Pujade-Lauraine, E., Aoki, D., Mirza, M. R., Lorusso, D., Oza, A. M., du Bois, A., Vergote, I., Reuss, A., Bacon, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw663 · Cited by 289
Self-citationThe Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Worzfeld, T., Pogge von Strandmann, E., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 288
Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
Romero, I., & Bast, R. C. (2012) · Endocrinology · doi:10.1210/en.2011-2123 · Cited by 286
Self-citationExosomes Increase the Therapeutic Index of Doxorubicin in Breast and Ovarian Cancer Mouse Models
Hadla, M., Palazzolo, S., Corona, G., Caligiuri, I., Canzonieri, V., Toffoli, G., & Rizzolio, F. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0154 · Cited by 282
Tan, T. Z., Miow, Q. H., Huang, R. Y., Wong, M. K., Ye, J., Lau, J. A., Wu, M. C., Bin Abdul Hadi, L. H., Soong, R., Choolani, M., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201823 · Cited by 281
Zhang, W., Klinkebiel, D., Barger, C. J., Pandey, S., Guda, C., Miller, A., Akers, S. N., Odunsi, K., & Karpf, A. R. (2020) · Cancers · doi:10.3390/cancers12030764 · Cited by 277
Horikawa, N., Abiko, K., Matsumura, N., Hamanishi, J., Baba, T., Yamaguchi, K., Yoshioka, Y., Koshiyama, M., & Konishi, I. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0387 · Cited by 275
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Wang, Y. K., Bashashati, A., Anglesio, M. S., Cochrane, D. R., Grewal, D. S., Ha, G., McPherson, A., Horlings, H. M., Senz, J., Prentice, L. M., et al. (2017) · Nature Genetics · doi:10.1038/ng.3849 · Cited by 273
Özeş, A. R., Miller, D. F., Özeş, O. N., Fang, F., Liu, Y., Matei, D., Huang, T., & Nephew, K. P. (2016) · Oncogene · doi:10.1038/onc.2016.75 · Cited by 265
Self-citationCell Origins of High-Grade Serous Ovarian Cancer
Kim, J., Park, E., Kim, O., Schilder, J., Coffey, D., Cho, C.-H., & Bast, R. (2018) · Cancers · doi:10.3390/cancers10110433 · Cited by 264
Self-citationHomologous recombination deficiency and ovarian cancer
Ledermann, J. A., Drew, Y., & Kristeleit, R. S. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.005 · Cited by 258
CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
Turcotte, M., Spring, K., Pommey, S., Chouinard, G., Cousineau, I., George, J., Chen, G. M., Gendoo, D. M. A., Haibe-Kains, B., Karn, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3569 · Cited by 257
Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C., Prentice, L. M., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072162 · Cited by 253
Rizvi, I., Gurkan, U. A., Tasoglu, S., Alagic, N., Celli, J. P., Mensah, L. B., Mai, Z., Demirci, U., & Hasan, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216989110 · Cited by 234
Acquired chemotherapy resistance in ovarian cancer
Christie, E. L., & Bowtell, D. D. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx446 · Cited by 220
Self-citationMicro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy
Astolfi, M., Péant, B., Lateef, M. A., Rousset, N., Kendall-Dupont, J., Carmona, E., Monet, F., Saad, F., Provencher, D., Mes-Masson, A.-M., et al. (2016) · Lab on a Chip · doi:10.1039/c5lc01108f · Cited by 182
Noninvasive ovarian cancer biomarker detection via an optical nanosensor implant
Williams, R. M., Lee, C., Galassi, T. V., Harvey, J. D., Leicher, R., Sirenko, M., Dorso, M. A., Shah, J., Olvera, N., Dao, F., et al. (2018) · Science Advances · doi:10.1126/sciadv.aaq1090 · Cited by 183
“Among all populations, the 5-year survival rate is just 46% (5).”
BackgroundSelf-citationTherapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00570 · Cited by 179
Marchini, S., Fruscio, R., Clivio, L., Beltrame, L., Porcu, L., Nerini, I. F., Cavalieri, D., Chiorino, G., Cattoretti, G., Mangioni, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.026 · Cited by 176
Ma, Y., Wang, W., Idowu, M. O., Oh, U., Wang, X.-Y., Temkin, S. M., & Fang, X. (2018) · Cancers · doi:10.3390/cancers11010033 · Cited by 145
Hallas-Potts, A., Dawson, J. C., & Herrington, C. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41941-4 · Cited by 110
The important roles of steroid sulfatase and sulfotransferases in gynecological diseases
Rižner, T. L. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00030 · Cited by 98
Lau, T.-S., Chan, L. K.-Y., Wong, E. C.-H., Hui, C. W.-C., Sneddon, K., Cheung, T.-H., Yim, S.-F., Lee, J. H.-S., Yeung, C. S.-Y., Chung, T. K.-H., et al. (2017) · Oncogene · doi:10.1038/onc.2016.509 · Cited by 88
The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels
Alsina‐Sanchis, E., Figueras, A., Lahiguera, Á., Vidal, A., Casanovas, O., Graupera, M., Villanueva, A., & Viñals, F. (2016) · International Journal of Cancer · doi:10.1002/ijc.30233 · Cited by 57
“>90% of ovarian tumors have an epithelial origin and can be classified into four main histological types: high-grade serous (70% of cases; the more aggressive type), endometrioid, mucinous and clear cell tumors.(2) Although”
BackgroundFinkernagel, F., Reinartz, S., Schuldner, M., Malz, A., Jansen, J. M., Wagner, U., Worzfeld, T., Graumann, J., von Strandmann, E. P., & Müller, R. (2019) · Theranostics · doi:10.7150/thno.37549 · Cited by 55
An omentum-inspired 3d peg hydrogel for identifying ecm-drivers of drug resistant ovarian cancer
Brooks, E. A., Gencoglu, M. F., Corbett, D. C., Stevens, K. R., & Peyton, S. R. (2019) · APL Bioengineering · doi:10.1063/1.5091713 · Cited by 51
Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer
Velletri, T., Villa, C. E., Cilli, D., Barzaghi, B., Lo Riso, P., Lupia, M., Luongo, R., López-Tobón, A., De Simone, M., Bonnal, R. J. P., et al. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-021-00878-w · Cited by 48
Heredia-Soto, V., Redondo, A., Berjón, A., Miguel-Martín, M., Díaz, E., Crespo, R., Hernández, A., Yébenes, L., Gallego, A., Feliu, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25098 · Cited by 33
Townsend, K. N., Spowart, J. E., Huwait, H., Eshragh, S., West, N. R., Elrick, M. A., Kalloger, S. E., Anglesio, M., Watson, P. H., Huntsman, D. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082406 · Cited by 29
“The survival rate of ovarian carcinoma patients has not changed over the past 30 years since the introduction of platinum-based chemotherapy treatment [2] and it is the most lethal of the gynecological malignancies [1].”
Microtubule inhibitor, SP-6-27 inhibits angiogenesis and induces apoptosis in ovarian cancer cells
Kulshrestha, A., Katara, G. K., Ibrahim, S. A., Patil, R., Patil, S. A., & Beaman, K. D. (2017) · Oncotarget · doi:10.18632/oncotarget.17549 · Cited by 26
Gambaro, K., Quinn, M. C., Cáceres-Gorriti, K. Y., Shapiro, R. S., Provencher, D., Rahimi, K., Mes-Masson, A.-M., & Tonin, P. N. (2015) · BMC Cancer · doi:10.1186/s12885-015-1138-8 · Cited by 21
“relapse rate to paclitaxel/carboplatin chemotherapy following cytoreductive surgery, which is the standard of care for patients [3,4].”
BackgroundSelective Covalent Targeting of Pyruvate Kinase M2 Using Arsenous Warheads
Wang, J., Zhou, S., Cheng, Y., Cheng, L., Qin, Y., Zhang, Z., Bi, A., Xiang, H., He, X., Tian, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01563 · Cited by 18
Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer
Li, W., Zhang, H., Yang, L., & Wang, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9653 · Cited by 9
Metadata
- Authors
- Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., Friedlander, M., Gabra, H., Kaye, S. B., Lord, C. J., Lengyel, E., Levine, D. A., McNeish, I. A., Menon, U., Mills, G. B., Nephew, K. P., Oza, A. M., Sood, A. K., Stronach, E. A., Walczak, H., Bowtell, D. D., & Balkwill, F. R.
- Venue
- Nature Reviews Cancer
- Published
- 2011-09-23
- Volume
- 11
- Issue
- 10
- Pages
- 719-725
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2075711878
- Cited by
- 1,464
- References
- 81
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.